Phase II Study of Peginterferon Alfa-2b (PEGIntron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma

Official Title: Phase II Study of Peginterferon Alfa-2b (PEGIntron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma

This phase II trial studies how well peginterferon alfa-2b works in treating younger patients with craniopharyngioma that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may interfere with the growth of tumor cells and slow the growth of craniopharyngioma.

ClinicalTrials.gov ID: NCT01964300

Principal Investigator: Goldman, Stewart, MD

Study Type: Interventional

Currently Recruiting Patients: Yes

Contact Information:

Stewart Goldman, MD

312.227.4844

Specialties & Conditions

Patients & Visitors

Plan Your Visit

While You're Here

After Your Visit

Research Innovation

Phase II Study of Peginterferon Alfa-2b (PEGIntron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma

Official Title: Phase II Study of Peginterferon Alfa-2b (PEGIntron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma

Contact Information:

Find

Get in Touch

Get to Know Us

For Healthcare Professionals